An Italian team has made a
breakthrough in leukemia research raising fresh hope of treating
the blood cancer better.
The team has shown the effectiveness of treatment with
lab-engineered cells dubbed CARCIK on acute lymphoblastic
leukemia (ALL) in children and adults.
Using the new cells, six out of seven treated patients showed a
complete disappearance of the cancer, a success rate of 86%.
The clinical study was carried out by researchers from
Fondazione Tettamanti labs, coordinated by the children's blood
cancer centre of the Fondazione Monza e Brianza per il Bambino e
la Mamma, with the collaboration of Bergamo's Papa Giovanni
XXIII Hospital.
The study was published in the Journal of Clinical
Investigation.
Th cells in question are special CAR-T cells obtained from the T
immune system of healthy donors, tweaked in the laboratory so as
to boost their capacity to recognize and kill cancer cells.
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid
line of blood cells characterized by the development of large
numbers of immature lymphocytes.
Symptoms may include feeling tired, pale skin color, fever, easy
bleeding or bruising, enlarged lymph nodes, or bone pain.
As an acute leukemia, ALL progresses rapidly and is typically
fatal within weeks or months if left untreated.
ALL is typically treated initially with chemotherapy aimed at
bringing about remission. This is then followed by further
chemotherapy typically over a number of years.
The new Italian study offers hope of finding a cure for the
disease.
ALL RIGHTS RESERVED © Copyright ANSA
